Abstract
Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset of non-small cell lung cancer (NSCLC). The rapid progression of ALK inhibitors......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
